Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Santander to buy TSB from Sabadell for £2.65bn

(Sharecast News) - Spanish banking group Santander has announced the acquisition of TSB for £2.65bn, making it the third-largest bank in the country in terms of personal current account balances. Santander will buy the lender from Spanish peer Banco de Sabadell for €3.1bn in an all-cash transaction, it announced late on Tuesday.

TSB, which has network of 218 branches and outlets, serves around 5m customers across retail and commercial banking, with £34bn in mortgages and £35bn in deposits.

Once combined with Santander UK, which operates 349 branches, the enlarged group would serve around 28m retail and business customers nationwide.

However, it is not clear at this stage whether TSB would face any branch closures or job cuts from its 5,000-strong workforce. A Santander UK spokeperson was quoted by the BBC as saying it would "make no sense" to have two branches from the same group in a single location.

"This is an excellent deal for customers combining two strong and complementary banks, creating one of the most substantial banks in the UK and materially enhancing the competitiveness of the industry," said Mike Regnier, chief executive of Santander UK.

"This deal accelerates our transformation allowing us to enhance our customer proposition and invest more in innovative products and our digital offering, supported by the human touch service so many appreciate, not least in our new branch formats and enhancements across the country," Regnier said.

The deal is still subject to regulator approvals and the green light from Sabadell shareholders, but is expected to complete in the first quarter of 2026.

UK-listed shares of Banco Santander were up 1.7% at 608.25p in London, while Sabadell climbed 2.4% to €2.77 in Madrid.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.